Antibody-free nanoconjugates using Angiopep-2 and PD-L1 antagonist peptide P-12 crossed the blood-brain barrier via LRP-1 transcytosis, activated T cell-mediated tumor killing in glioblastoma models, and showed enhanced brain accumulation with a favorable safety profile.
BBB crossing + immunotherapyAntibody-free peptide nanoconjugates deliver PD-L1 blockade across the blood-brain barrier for glioblastoma, with confirmed brain accumulation
What the researchers found
P-12/AP-2/NCs crossed in vitro BBB, internalized in 3D GBM spheroids, mediated T cell cytotoxicity, selectively inhibited PD-1/PD-L1, increased inflammatory cytokines and T cell proliferation, showed significantly increased brain accumulation (2-6h post-injection), and were safe at low and high doses.
Why it matters
Glioblastoma has dismal survival (<8 months) partly because the blood-brain barrier blocks most treatments. An antibody-free, peptide-based system that delivers immunotherapy across the BBB could transform treatment of this lethal cancer.
How the study worked
Nanoconjugate synthesis with PMLA polymer, in vitro BBB-Transwell spheroid model, T cell cytotoxicity assays, PD-1/PD-L1 inhibition studies, in vivo mouse brain distribution imaging, and histopathology safety evaluation.
What this study cannot tell us
Preclinical study with in vitro BBB model (not actual human BBB). No in vivo tumor efficacy or survival data. Brain accumulation shown but therapeutic concentrations not confirmed. 3D spheroid model does not replicate tumor microenvironment complexity.
How to read the evidence
Preclinical proof-of-concept with in vitro BBB model, 3D tumor model, and in vivo biodistribution. Strong engineering but lacks in vivo efficacy data.
When this study was published
Published in 2025; represents frontier research in brain-targeted peptide immunotherapy.
The bigger picture
This programmable nanoconjugate platform could be adapted for other brain diseases beyond glioblastoma, using different therapeutic peptides with the same BBB-crossing mechanism. The antibody-free design reduces manufacturing complexity and immunogenicity.
Questions still open
- Does the nanoconjugate produce anti-tumor efficacy in orthotopic GBM mouse models?
- How does BBB penetration compare to antibody-drug conjugates?
- Can the platform deliver other therapeutic peptides for neurodegenerative diseases?
Common questions
Why is brain cancer so hard to treat?
How do these peptide nanoparticles get into the brain?
Read the original research
Antibody-Free Immunopeptide Nanoconjugates for Brain-Targeted Drug Delivery in Glioblastoma Multiforme.
Bioconjugate chemistry, 36(10), 2132-2144
Citation
Sharma, Saurabh; Lee, David; Maity, Surjendu; Singh, Prabhjeet; Chadokiya, Jay; Mohaghegh, Neda; Hassani, Alireza; Kim, Hanjun; Gangarade, Ankit; Ljubimova, Julia Y; Kirane, Amanda; Holler, Eggehard. (2025). Antibody-Free Immunopeptide Nanoconjugates for Brain-Targeted Drug Delivery in Glioblastoma Multiforme.. Bioconjugate chemistry, 36(10), 2132-2144. https://doi.org/10.1021/acs.bioconjchem.5c00168